BETOPTIC S Drug Patent Profile

When do Betoptic S patents expire, and what generic alternatives are available?

Betoptic S is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in BETOPTIC S is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betoptic S

A generic version of BETOPTIC S was approved as betaxolol hydrochloride by EPIC PHARMA on October 22^nd, 1999.

Summary for BETOPTIC S

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for BETOPTIC S

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	BETOPTIC S	betaxolol hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	019845-001	Dec 29, 1989		RX	Yes	Yes

International Patents for BETOPTIC S

See the table below for patents covering BETOPTIC S around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	1607495
Australia	4575389
Australia	621692

Last updated: February 9, 2026

What Is the Market Position of BETOPTIC S?

BETOPTIC S is a combination ophthalmic solution containing betaxolol and bromfenac, used primarily for the treatment of ocular hypertension, glaucoma, and postoperative inflammation. It targets a niche market within ophthalmology, especially in cases requiring both intraocular pressure reduction and control of inflammation.

Market adoption hinges on several factors:

• Efficacy and safety profile: BETOPTIC S combines a beta-blocker with an NSAID, which may reduce the need for multiple medications.
• Competitive landscape: Alternatives include generic beta-blockers, NSAIDs, and combination therapies like Cosopt (dorzolamide/timolol) or Xalacom (latanoprost/timolol).

Estimated global market size for glaucoma drugs approaches $5.8 billion (2022), with growth driven by aging populations and increasing disease prevalence.

What Are the Key Regulatory and Patent Factors?

Regulatory approvals:

• BETOPTIC S is approved in select markets, with some regions requiring local registration.
• Patent protections typically extend FDA exclusivity up to 2025, with coverage in Europe and Asia varying by jurisdiction.

Patent landscape:

• Existing patents cover betaxolol and bromfenac separately.
• No recent patents have been filed specifically for the combination, increasing potential for generic competition post-expiry.
• Patent expirations expected around 2025-2026, opening opportunities for biosimilars or generics.

How Does BETOPTIC S Compare to Competitors?

Feature	BETOPTIC S	Cosopt	Xalacom
Active Ingredients	Betaxolol + bromfenac	Dorzolamide + timolol	Latanoprost + timolol
Indications	Glaucoma, ocular hypertension	Glaucoma, ocular hypertension	Glaucoma, ocular hypertension
Routes of administration	Ophthalmic solution	Ophthalmic solution	Ophthalmic solution
Market presence	Limited, niche indication	Market leader in combination therapy	Competitive, established product

BETOPTIC S’s advantage lies in its dual mechanism targeting inflammation and pressure, but it faces competition primarily on marketing, price, and patient acceptance.

What Are the Investment Risks?

• Patent expiration: The expiration around 2025 means generic entrants can significantly erode market share.
• Regulatory hurdles: Market entry in some countries remains slow and costly.
• Market penetration: Adoption depends on prescriber familiarity and preference for existing therapies.
• Pricing pressures: Generic competition drives down prices, impacting profit margins.

What Are the Opportunities for Growth?

• Market expansion: Entry into emerging markets with rising glaucoma prevalence.
• New formulations: Development of sustained-release or preservative-free versions.
• Label expansion: Pursuit of additional indications such as dry eye or conjunctivitis.

What Financial Metrics Are Relevant?

• Revenue estimations: Assuming a 2% global market share of the glaucoma segment, revenue could approximate $116 million annually. Growth depends on market penetration and pricing strategies.
• Cost structure: R&D expenses for combination drugs are moderate, but marketing and regulatory costs are substantial.
• Profit margins: Generic competition can reduce gross margins from 70% to below 50%, depending on market exclusivity.

How Will Market Dynamics Evolve?

• Patent cliffs around 2025 will introduce price competition.
• Regulatory pathways for biosimilars could shorten development timelines.
• Aging demographics will sustain demand growth in developed markets.

Key Takeaways

• BETOPTIC S addresses a specific niche with a potential for revenue in glaucoma management.
• Patent expiry around 2025 presents a significant risk for revenue erosion.
• Competition from generics and established brands dominates the market.
• Growth prospects depend on geographic expansion and formulation innovation.
• Market entry and pricing strategies must navigate regulatory and competitive challenges.

FAQs

1. When do patents for BETOPTIC S expire?
Patent protections are expected to expire around 2025-2026, depending on jurisdiction.

2. How does the combination therapy benefit patients?
It simplifies treatment by addressing both intraocular pressure and inflammation, potentially increasing adherence.

3. What is the main competition?
Generic beta-blocker solutions and combination therapies like Cosopt and Xalacom dominate the market.

4. Is there potential for new formulations?
Yes, sustained-release and preservative-free versions could expand application and patient compliance.

5. What markets offer the best growth opportunity?
Emerging markets with rising glaucoma prevalence and less mature regulatory environments present growth potential.

---

Sources:
[1] MarketWatch - Glaucoma Drugs Market, 2023
[2] Company filings and patent databases (WIPO, USPTO)
[3] GlobalData Healthcare Reports, 2022